New drug aramchol aims to reverse fatty liver damage in phase 3 trial
NCT ID NCT04104321
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called Aramchol for people with nonalcoholic steatohepatitis (NASH), a serious fatty liver disease that can lead to scarring. About 150 adults with NASH and liver scarring (stages 1-3) will take Aramchol or a placebo for up to 72 weeks. The goal is to see if the drug can reduce liver scarring and improve liver health. The study was paused due to COVID-19 and results are expected in 2027.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NONALCOHOLIC STEATOHEPATITIS (NASH) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Texas Clinical Research Institute, LLC
Arlington, Texas, 76012, United States
-
The Public Health Trust of Miami-Dade County, Florida, dba the Jackson Health System
Miami, Florida, 33136, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single pill tackle both fatty liver and diabetes?
- New drug miricorilant tested for fatty liver disease safety
- New drug shows promise against fatty liver disease in Mid-Stage trial
- New drug aims to shrink fatty liver in early trial
- New shot shows promise for fatty liver disease in early trial
- New drug aims to melt liver fat in NASH patients